The oral administration of Bifidobacteria alone improved tumor control with PD-L1-specific antibody treatment, and combination therapy almost suppressed tumor growth, which may influence the therapeutic response to anti-PD-1 at the level of the tumor microenvironment [54]. Here, CD274 is linked to neoplasm.